HHS RESTRUCTURING CUTS 10,000 JOBS AMID BUDGET REDUCTION
The U.S. Health and Human Services Department (HHS) is undergoing a significant restructuring, with up to 10,000 layoffs expected, following an announcement from Health Secretary Robert F. Kennedy Jr. The plan consolidates several agencies and aims to streamline the department, which oversees health trends, disease outbreaks, medical research, and health insurance programs. The cuts will reduce HHS’s workforce by nearly 25%, impacting 10,000 jobs through layoffs and early retirements. Among the agencies affected are the FDA, CDC, NIH, and CMS. The restructuring also includes a major budget reduction, with over $11 billion in COVID-19-related funding pulled from state and local health departments, resulting in additional job losses. The move follows President Trump’s decision to strip workers of collective bargaining rights, a controversial action condemned by some lawmakers. Critics argue these changes will undermine public health efforts, particularly during emergencies like disease outbreaks. (AP)
DRUGMAKERS LOBBY TRUMP FOR STAGED PHASE-IN OF TARIFFS
Drugmakers are lobbying President Donald Trump to implement a gradual phase-in of tariffs on imported pharmaceuticals to reduce the immediate impact and allow time for shifting manufacturing to the U.S. While Trump plans to announce new tariffs soon, including on the pharmaceutical sector, the specifics remain unclear. Drug companies are seeking a staged increase toward the 25% tariff Trump has threatened, as moving production to the U.S. is costly and time-consuming, taking 5 to 10 years and up to $2 billion to set up new facilities. The industry hopes for a lower initial tariff to avoid drug shortages and ensure continued access for patients. Some pharmaceutical companies have already invested billions in U.S. production, but many still rely on overseas manufacturing, particularly in Europe. As the U.S. considers these tariffs, drugmakers are preparing for potential disruptions by increasing air shipments of medicines. (Reuters)
TRUMP CRITICIZES SMITHSONIAN EXHIBITION ON RACE AND SCULPTURE
President Trump issued an executive order criticizing the Smithsonian Institution’s exhibition, *The Shape of Power: Stories of Race and American Sculpture*, accusing it of promoting a “divisive, race-centered ideology.” The exhibition explores how sculptures have shaped and reflected racial attitudes in the U.S., including the view that race is a social construct rather than a biological reality. Scholars, including Samuel J. Redman, argue that this view is widely accepted today and that the executive order is out of step with current consensus. The exhibition highlights how race has been used to establish systems of power, privilege, and oppression. Some of the artists featured, such as Roberto Lugo and Nicholas Galanin, emphasized that their works aimed to foster understanding, not divisiveness. Art historian James Smalls criticized the order for silencing important discussions about race and history, asserting that museums should confront difficult historical truths rather than suppress them for political convenience. (New York Times)
RESEARCH REVEALS CYSTEINE KNOTS STABILIZE COLLAGEN STRUCTURE
Collagen, a key protein in the body, is essential for providing structural support to cells and tissues. However, it is inherently unstable at body temperature. Recent research revealed that collagen’s stability is maintained by clusters of sulfur-rich “cysteine knots,” which act as molecular “staples” that help collagen maintain its structure. These findings, presented at the American Physics Society’s Global Summit, offer insights into how collagen can remain stable despite its thermal instability. By using atomic force microscopy, researchers discovered that disulfide bonds between collagen strands allow the protein to refold and retain its twisted triple-helix structure. This discovery could help bioengineers design more stable materials for tissue engineering and provide insights into connective tissue diseases like osteogenesis imperfecta and Ehlers-Danlos syndrome. The research also highlights the evolutionary conservation of cysteine knots, suggesting their crucial role in collagen’s resilience across different organisms. (Science)
Sign up for the Daily Dose Newsletter and get every morning’s best science news from around the web delivered straight to your inbox? It’s easy like Sunday morning.
CERN UNVEILS BLUEPRINT FOR FUTURE CIRCULAR COLLIDER PROJECT
CERN has unveiled a blueprint for the Future Circular Collider (FCC), a proposed successor to the Large Hadron Collider (LHC) designed to explore deeper questions in physics. The FCC, spanning nearly 91 kilometers (56.5 miles) beneath the French-Swiss border, aims to conduct high-precision experiments starting in the mid-2040s, followed by high-energy proton and ion collisions in the 2070s. This advanced collider would operate at 10 times the energy of the LHC, enabling the creation of heavier particles. With an estimated cost of $16 billion, the project is under review, with a decision expected by CERN’s member countries in 2028. The FCC promises breakthroughs in areas like cryogenics, superconducting magnets, and vacuum technology. It also offers the potential to advance understanding of the Higgs boson and other fundamental forces. The project follows a decade of planning, with experts anticipating its contribution to future physics discoveries on a global scale. (AP)
NATALIA TRAYANOVA ADVANCES CARDIAC DISEASE TREATMENT WITH AI
Natalia Trayanova, a biophysicist at Johns Hopkins University, is revolutionizing the treatment of cardiac diseases through computational cardiology. She creates personalized virtual hearts for patients, using advanced imaging and AI to simulate heart functions and predict treatment outcomes, such as arrhythmia interventions. Trayanova’s work addresses sudden cardiac arrest, the leading cause of death, and other cardiac conditions. By building digital twins of the heart, including detailed tissue and fibrosis models, doctors can test treatment options and precisely target interventions. Though currently resource-intensive, advancements in AI are making these simulations faster and more accessible for routine clinical use. Trayanova also emphasizes the need for AI in medicine to be transparent and trusted by doctors. While she acknowledges the potential of AI in healthcare, she critiques the Trump administration’s cuts to biomedical research funding, which she believes could stifle scientific progress and harm U.S. leadership in biomedicine. (El Pais)
IMAGE CREDIT: NASA.